ONS logo

Cancer Genetics

special interest group newsletter

Volume 19, Issue 2, November 2015  
Coordinator’s Message: Transitioning to
the Future and the Evolution of SIGs

Catherine M. Belt, RN, MSN, AOCN®
Philadelphia, PA

c belt

Catherine M. Belt

Survival of the fittest, a saying often attributed to Charles Darwin, was coined by British economist Herbert Spencer in his 1864 book Principles of Biology to describe Darwin's theory of natural selection (Scoville, 2015). Spencer used this phrase to capture the economic theory that adaptation to an environment is critical for survival. The concept was widely adopted and applied to business and management practices. Continuous process improvement is now a central dogma by which organizations evaluate their effectiveness and plan for the implementation of change strategies.

Change surrounds us every day no matter the circumstances or situations on both personal and professional levels. We have certainly experienced change in the healthcare environment. The Affordable Care Act, the Human Genome Project, and personalized medicine are influencing clinical practice. Community hospitals and academic facilities are partnering and merging to adapt. Healthcare professionals are more diverse in cultural and ethnic profiles, academic preparation, and generational differences. Responding to change in a thoughtful manner can make the difference between the survival and failure of an organization. In 2014, ONS began an assessment of the organization, its membership profile, the structure of its leadership development, and necessary measures to be taken in the 21st century to ensure its survival as the premier oncology nursing organization. A task force with members from the Special Interest Group Council, ONS board, and ONS staff in collaboration with a management consulting team considered the future of the SIGs. SIGs are faced with limited member participation, communication difficulties, and a lack of leadership succession planning. ONS represents a large cross-section of multigenerational membership. The majority of ONS members are approaching retirement age, and there is a lack of engagement in younger generations. The task force proposal submitted to the ONS board attempts to address these issues as it redefines and reinvents the SIG community. Over the course of the next year, you will see many of these recommended changes in action.

SIGs will evolve into learning communities that emphasize greater flexibility, a broader appeal, and increased engagement with ONS’s membership. The implementation of a streamlined, easy-to-access, web-based communication platform will be central to this concept. ONS is selecting a system that will eliminate the challenges that users currently experience with the Virtual Communities and discussion boards.

During the next 12-18 months, the SIG structure will be in transition. SIG newsletter requirements, coordinator communiqués, annual strategic goal planning, and summary reporting will be reduced or eliminated. The Cancer Genetics (CAG) SIG leadership team elected to continue these forms of communication while the new structure is implemented phased in.

SIGs’ presence at the ONS Congress in 2016 also will change. The CAG SIG leadership team submitted seven podium presentation topics to the Congress Planning team and hopes that one or more topics will be selected. The SIG also will have the opportunity to develop a specific CNE topic at Congress. Our 2015 Congress CAG SIG presentations had excellent attendance rates and outstanding evaluations. We want to capitalize on these successes for the 2016 Congress in San Antonio, TX.

The full proposal formulated by the task force is posted on the SIG Virtual Community. I encourage all our members to review this document.

These are challenging and exciting times for health care, oncology nursing practice, and the CAG SIG. The engagement of our SIG membership is critical to developing future involvement. If you have questions or would like to offer commentary, please communicate directly with CAG SIG leadership team members or share them on the SIG discussion board.


IScoville, H. (2015). Survival of the fittest? About.com. Retrieved from http://evolution.about.com/od/NaturalSelection/a/Survival-Of-The-Fittest.htm

Additional Resource

Oncology Nursing Society (2015). Knowledge Community Opportunities. Retrieved from http://cancergenetics.vc.ons.org/file_depot/0-10000000/0-10000/3362/associatedFiles/Community

The Cancer Genetics SIG Newsletter is produced by members of the
Cancer Genetics SIG and ONS staff and is not a peer-reviewed publication.

Cancer Genetics

Special Interest Group Newsletter November 2015  
Living the Dream: Summer Genetics Institute at the
National Institutes of Health

Laurie Connors, DNP, APNG, FNP-BC, AGN-BC
Glenwood, NY
l connors

Laurie Connors

I was selected as one of 26 nurses to attend the June 2015 National Institute of Nursing Research (NINR) Summer Genetics Institute (SGI) at the National Institutes of Health (NIH). This article is a description of the month-long program and a reflection on my experiences at SGI.

The SGI Program: An Overview

The SGI program is intense and challenging with opportunities for advanced practice nurses to gain a basic understanding of molecular genetics applications and proficiency in laboratory procedures. As listed at the NINR website, course objectives are the following.

In August 2013, the DCN protocol office piloted a new subject screening process. Its objectives were to (a) develop an effective screening process, (b) increase enrollment, (c) identify enrollment barriers and opportunities for current and future trials, (d) establish the clinical trial nurse’s role in the screening process, and (e) enhance engagement between clinical trial nurses and community providers.

"Participants in the SGI will increase their knowledge of molecular genetics for use in research, teaching, and clinical practice. Specifically, they will be able to:

  • Use molecular genetics methods in bio-behavioral research in a laboratory setting
  • Analyze strategies used for genomic-based therapies and describe trends in the molecular therapeutics
  • Identify the strengths, weaknesses, and applications of genetic tests
  • Examine the ethical and legal issues related to genetic testing and genetic counseling and their implications for practice and research" (NINR, 2015).

I learned about genetics methods such as buccal cell DNA isolation, polymerase chain reaction, fluorescent in-situ hybridization, RNA analysis, microarrays, and cell cultures, and I practiced these techniques in the laboratory. In the classroom, world-renowned scientists gave lectures on cutting-edge topics in genomics and bioinformatics. I now understand how genomics is key to President Obama’s Precision Medicine Initiative (Office of the Press Secretary, 2015).

My SGI Colleagues

story 2 pic 1

Our class was comprised of nurses from 17 states. Our backgrounds, specialty areas, and associated genetic research interests were diverse and included cancer, symptomatology, gut microbiomes, pharmacogenomics, neurodevelopment, neonatal development, post-traumatic stress disorder prevention, neuronal pathways, biologic pathways, and sleep. We gelled well as a group and had great lunch and dinner conversations about plans for applying what we learned in practice and research. The days of training were long, but we were able to walk in the neighborhood for exercise and occasionally try some of the local restaurants. During brief downtimes, I expanded my genetics perspectives by reading The Language of God: A Scientist Presents Evidence for Belief (2006) by Francis Collins, MD, PhD, former director of the National Human Genome Research Institute and current director of NIH.

The NIH Campus Experience

The SGI classroom and genomics laboratory are located in the oldest building on the NIH campus and were formerly a convent for cloistered nuns. The architectural details contributed to an academic, almost spiritual environment. The SGI course was rigorous with lectures and laboratory exercises eight hours per day, five days per week, and weekend take-home quizzes. Scheduled field trips on the NIH campus gave us breaks from the intense classroom and laboratory schedules. We visited the National Library of Medicine, the home of PubMed, and saw the “Pictures of Nursing” collection, an amazing exhibit of images of nursing over the past century.

My SGI Colleagues

story 2 pic 2

We toured the NIH Clinical Center and had the privilege of attending cutting-edge NIH research lectures. I heard James Allison, PhD, from the MD Anderson Cancer Center in Houston, TX, lecture on cancer immune checkpoint blockades; MarySue V. Heilemann, PhD, RN, present on how nurses are portrayed in the media; and Medha Bhagwat, PhD, introduce big data with Online Mendelian Inheritance in Man, Exome Variant Server, Clinical Genomic Database, dbSNP, and ClinVar.

My Takeaways

Reflecting on my recent experience at NIH, I am humbled and honored to have this genetics training. I know that what I learned and experienced at SGI will change my career. I graduated with 149 lecture and lab hours and A’s in eight graduate credits from the Foundation for the Advanced Education in the Sciences. But more importantly, I gained a new perspective on the importance of genomics and the future of personalized medicine. SGI was a once-in-a-lifetime experience. I encourage nurses to pursue this intramural training award.


Collins, F. (2006). The language of god: A scientist presents evidence for belief. New York, NY: Free Press.

National Institute of Nursing Research. (2015). Summer Genetics Institute. Retrieved from https://www.ninr.nih.gov/training/trainingopportunitiesintramural/

Office of the Press Secretary. (2015). Fact sheet: President Obama’s precision medicine initiative. The White House Briefing Room. Retrieved from https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative

Laurie Connors started her career in oncology at the Roswell Park Cancer Institute in Buffalo, NY, in 1997 as a family nurse practitioner and has focused on clinical cancer genetics for the past five years. She is the director of clinical genetics at Comprehensive Cancer Services Oncology in Buffalo, NY, and is a clinical assistant professor at the State University of New York at Buffalo. With the knowledge she gained from the one-month research training program in molecular genetics, Laurie will build programs of nursing research in clinical cancer genetics that translate into personalized health care and precision medicine at her teaching institution.

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

The Case for Advanced Genetics Nursing Certification

Elisabeth M. King, MSN, RN, FNP-C, AGN-BC
Austin, TX

pulling files

Elisabeth M. King

Nurses have long been public health and preventive medicine advocates, so it is no surprise that many also take an interest in hereditary cancer syndromes. Although most cancers occur sporadically, a small subset of the population is born with an inherited gene mutation that increases cancer risk. Patients and their family members who have mutations in hereditary cancer genes are candidates for increased surveillance, chemoprevention, and risk-reduction surgery. The identification of hereditary cancer syndromes is important in reducing cancer risk and promoting early cancer detection.

Nurses have been involved in genetics in an official capacity since the early 1980s with the formation of the Genetics Nursing Network, which became the International Society of Nurses in Genetics (ISONG) (Greco & Mahon, 2002). ISONG approved the formation the Genetic Nursing Credentialing Commission (GNCC) in 2001, and shortly after, it credentialed the first genetics advanced practice nurses (APNs). This process was in place till December 2013. In December 2014, the American Nurses Credentialing Center (ANCC) launched a new certification for advanced genetics nurses (AGNs).

Our knowledge of clinical cancer genetics continues to grow, yet a surprisingly small number of APNs are certified in genetics. Although ANCC was not able to provide updated numbers, as of December 2013, only 50 APNs were certified in genetics (GNCC, n.d.).

Obtaining board certification in genetics validates an APN’s qualification to provide genomic-based health care. Certification is a credible way for APNs to validate their education and experience, continue learning, and be recognized for their enthusiasm, dedication, and contribution to cancer genetics.

In addition to the professional advantages of certification, there are benefits for insurance authorization and potential employer bonuses. In September 2013, Cigna (n.d.) implemented a policy requiring pre- and post-test counseling by a board-certified genetic counselor, clinical geneticist, or AGN for any patient receiving genetic testing. Cigna is the first of the large national insurance carriers to adopt this policy, but others may follow suit. Some employers offer financial incentives for certification although many do not have specific policies in place. An APN certified in genetics will likely be the first in his or her organization and may need to lead the charge for reevaluating compensation models.

The ANCC AGN certification process consists of a peer-reviewed portfolio evaluation that is renewed every five years (ANCC, n.d.a). Eligibility requirements include a current, active RN license, at least two years of full-time employment as an RN, a graduate degree in nursing, and a minimum of 1,500 practice hours in advanced genetics nursing in the past three years. Professional development requirements include continuing education and the fulfillment of two additional categories selected from the following.

  • Academic credits
  • Presentations
  • Publication or research
  • Preceptor
  • Professional service

I completed the portfolio process and received my certification in June 2015. Although the application is long and somewhat tedious, I found the ANCC website easy to navigate. When I had questions about the application, ANCC was quick to respond and was very helpful. ANCC (n.d.b) recently added a frequently-asked-questions section to its site, which reviews many of the questions I encountered during the application process.

The most challenging part of the certification was not the application process, but the professional development requirements. I started my oncology nursing journey with an undergraduate degree in biology and a specialization in genetics with years of molecular cancer genetics research. When I started working as an APN in oncology and decided to pursue the genetics certification, I already met many of the professional development requirements. Most nurses did not take this path and must build their portfolios from scratch. A careful review of ANCC’s requirements will allow APNs to set realistic, attainable goals and make a plan for accomplishing the professional development requirements.

Cancer genetics, like much of oncology, is a rapidly evolving, challenging, and tremendously rewarding field. APNs are well positioned to provide genomic-based health care and make unique contributions to improve the health of patients and their families. I encourage qualified nurses to pursue the ANCC genetics certification.


American Nurses Credentialing Center. (n.d.a). Advanced genetics nursing. Retrieved from http://www.nursecredentialing.org/advancedgenetics

American Nurses Credentialing Center. (n.d.b). Certification through portfolio application FAQs. Retrieved from http://www.nursecredentialing.org/CertificationPortfolioFAQs

Cigna. (n.d.). Genetic testing and counseling program. Retrieved from http://www.cigna.com/healthcare-professionals/resources-for-health-care-professionals/genetic-testing-and-counseling-program

Genetic Nursing Credentialing Commission. (n.d.). About. Retrieved from http://www.geneticnurse.org/

Greco, K., & Mahon, S. (2002). Genetics nursing practice enters a new era with credentialing. Internet Journal of Advanced Nursing Practice, 5(2). Retrieved from http://ispub.com/IJANP/5/2/8226

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Update on National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines™) in Oncology for Identifying and Managing Hereditary Cancer

Karen Heller, MS, CGC
Dallas, TX

Teri Howell, RN, BSN, OCN®
Suffolk, VA

k heller

Karen Heller

Teri Howell

Teri Howell

The National Comprehensive Cancer Network (NCCN) is an alliance of 25 of the world’s leading cancer centers that publishes the NCCN Clinical Practice Guidelines in Oncology, which include cancer treatment guidelines and several screening guidelines for certain cancers. In this article, we highlight select updates to the hereditary breast, ovarian, and colorectal cancer guidelines for 2015. Refer to the NCCN website for a complete review of the guidelines and all changes. Unless otherwise specified, all recommendations are category 2A, meaning that “based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate” (NCCN, 2015b).

Genetic/Familial High-Risk Assessment: Breast and Ovarian

This guideline includes testing and management guidance for hereditary breast and ovarian cancer (HBOC) as well as Li-Fraumeni and Cowden syndromes. There also is a section on multigene panel testing, which was added to the guidelines in September 2014 (NCCN, 2015b, p. 26).

Multigene (Panel) Testing

  • In each of the testing algorithms, including HBOC and Li-Fraumeni and Cowden syndromes, there is now the option to consider a multigene panel test as a first-tier test if appropriate or as a reflex test if no mutation is found on the single syndrome test (NCCN, 2015b). These options were added to the second version of the 2014 guidelines.
  • A table has been added summarizing breast and ovarian management based on genetic test results (NCCN, 2015b).
  • In addition to the management recommendations for the high penetrance genes already described in the NCCN Guidelines™, breast MRI is also now recommended for carriers the moderate penetrance genes ATM, CHEK2, and PALB2 (NCCN, 2015b).
  • The section on multi-gene testing contains some useful commentary, including the improved efficiency and cost-effectiveness of panel testing “when more than one gene can explain an inherited cancer syndrome;” the “role for multi-gene testing in individuals who have tested negative (indeterminate) for a single syndrome, but whose personal or family history remains strongly suggestive of an inherited susceptibility;” the importance of choosing the “specific laboratory and test panel;” the approach to moderate penetrance genes; “the increased likelihood of finding variants of unknown significance when testing for mutations in multiple genes;” and the ideal of offering multi-gene testing “in the context of professional genetic expertise for pre- and post-test counseling” (NCCN 2015a, GENE-1).
Hereditary Breast and Ovarian Cancer

New Testing Criteria

The testing criteria for patients younger than 50 years diagnosed with breast cancer were broadened. Besides having an additional primary breast cancer, at least one relative with breast cancer at any age, or an unknown or limited family history, two additional criteria are provided for this population.

  • At least one relative with pancreatic cancer
  • At least one relative with prostate cancer (Gleason score ≥ 7) (NCCN, 2015b, HBOC-1)
  • (Note that the guidelines consider first-, second-, and third-degree relatives.)

Individuals with prostate (Gleason score ≥ 7) or pancreatic cancer at any age no longer need to have two affected relatives to meet the criteria for testing; just one relative with breast (younger than 50 years), ovarian, or pancreatic cancer is needed. In addition, a patient with prostate cancer (Gleason score ≥ 7) meets the criteria if he has a single relative with prostate cancer (Gleason score ≥ 7) (NCCN 2015a, HBOC-1).

Ashkenazi Jewish patients with pancreatic cancer no longer require any additional significant family history to meet criteria for testing (NCCN, 2015b).

  • For patients with HBOC who did not elect to have risk-reducing salpingo-oophorectomy, transvaginal ultrasounds and cancer antigen 125 testing may be considered at the clinician’s discretion. However, the caveats are emphasized, and NCCN (2015) noted that “while there may be circumstances where clinicians find screening helpful, data do not support routine ovarian screening.” In addition, “salpingectomy alone is not the standard of care and is discouraged outside a clinical trial” (NCCN 2015a, HBOC-A).
  • Among women with a BRCA mutation who are treated for breast cancer, the screening of remaining breast tissue with annual mammography and breast MRI should continue” (NCCN 2015a, HBOC-A).
  • For men with HBOC, the recommendation for mammography has been removed. Medical management for men continues to include breast self and clinical examinations starting at age 35 and prostate screening starting at age 40 (NCCN 2015a, HBOC-A).
Li-Fraumeni Syndrome Management

An annual whole-body magnetic resonance image including the brain is now recommended. Previously, the NCCN (2015b) suggested discussing participation in novel screening approaches. In addition, annual dermatologic examinations are recommended (NCCN, 2015b).

Genetic/Familial High-Risk Assessment: Colorectal

This guideline was new in 2014 and includes testing and management for Lynch syndrome (LS) and the various polyposis syndromes.

Lynch Syndrome
  • The testing criteria are unchanged from 2014 and include directions to consider individuals with a 5% or greater risk of LS on the MMRpro, PREMM, or MMRpredict risk models (NCCN, 2015b, LS-1).
  • The management section now recommends advising relatives about their risks and the availability of genetic counseling and testing as well as advising patients about reproductive risks and options (NCCN, 2015b, LS-4).

The chart, “Tumor Testing Results and Additional Testing Strategies,” was revised to include more possible explanations for various abnormal immunohistochemistry (IHC) results (NCCN, 2015c, p. 16). Accordingly, when IHC results implicate a particular gene or genes, LS genetic testing is now recommended, defined as “testing of the gene/s that are indicated [. . .] or instead, multi-gene testing” that includes all of the Lynch genes concurrently (i.e., the option to test all Lynch genes concurrently versus individually based on IHC result) (NCCN, 2015c). There is an added recommendation to consider somatic mismatch repair mutation testing of tumors in some instances when germline testing is negative. A new footnote was added concerning the possibility of absent MSH6 staining in rectal tumor tissue secondary to neoadjuvant chemoradiotherapy (NCCN 2015b, LS-A).

Familial Adenomatous Polyposis
  • In the 2014 guidelines, the criteria for APC and MUTYH gene testing required greater than 10 adenomas. This year, the criteria 20 or more adenomas, but there is an added recommendation to consider testing when 10-20 adenomas are present, depending on “age of onset, family history and/or presence of other features.” In addition to the presence of a desmoid tumor, consideration for APC testing can be based on a patient’s personal history of hepatoblastoma or a cribriform-morular variant of papillary thyroid cancer depending on the clinical history (NCCN 2015b, APC/MUTYH-1).
  • For the extracolonic management of attenuated familial adenomatous polyposis, patients aged 20-25 years should begin receiving upper endoscopies (rather than 25-30), and they should begin earlier if a colectomy was performed before age 20 (NCCN 2015b, AFAP-1).

The NCCN Guidelines™ are updated at least annually, and oncology practitioners should be familiar with the most current guidelines. The complete guidelines, including discussion sections, provide an excellent review of conditions. They can be accessed with a free registration on NCCN’s website.


National Comprehensive Cancer Network. (2015a). NCCN categories of evidence and consensus. Retrieved from http://www.nccn.org/professionals/physician_gls/categories_of_consensus.asp

National Comprehensive Cancer Network. (2015b). NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Breast and ovarian [v.2.2015]. Retrieved from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

National Comprehensive Cancer Network. (2015c). NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Colorectal [v.1.2015]. Retrieved from http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf

Referenced from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for “Genetic/Familial High-Risk Assessment: Breast and Ovarian” and “Genetic/Familial High-Risk Assessment: Colorectal.” © National Comprehensive Cancer Network, 2015. All rights reserved. Accessed September 5, 2015. To view the most recent and complete version of the guidelines, visit the NCCN website. National Comprehensive Cancer Network®, NCCN®, NCCN Guidelines™, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Cancer Genetics SIG Member News


Photo courtesy of Pixabay

Congratulations to Julia Ann Nunemaker Eggert, PhD, RN, AGN-BC, GNP-BC, AOCN®, for being selected as a fellow in the American Academy of Nursing (FAAN). Julie is one of 163 nurse leaders from across the country to receive this honor. Julie has many scholarly achievements in research, education, and practice with an emphasis on genetics and genomics. Julie is the coordinator-elect of the Cancer Genetics SIG and co-editor of the Cancer Genetics SIG Newsletter. Julie will begin using the FAAN credential after the October 2015 induction ceremony.

SIG member Lisa B. Aiello, RN, MSN, AOCNS®, APRN, advocated for a designated genetics and genomics column in the Oncology Nursing Forum (ONF) and was subsequently named its associate editor. Lisa is a pioneer and champion for genetics and genomics education for oncology nurses. In 2016, Lisa will hand the pen to Suzanne Mahon, RN, DNSc, AOCN®, APNG, who will become the next associate editor of the ONF genetics and genomics column. If you are interested in writing a short article for the ONF genetics and genomics column, contact Suzanne.

Please send Cancer Genetics SIG member updates and celebrations to Patricia Kelly, DNP, RN, CNS, AGN-BC, AOCN® (SIG newsletter editor) or to Julie Eggert, PhD, RN, AGN-BC, GNP-BC, AOCN® (SIG newsletter co-editor).

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Get Involved With the ONS Journals: Join the Peer Review Board

peer review

Courtesy of AJC Photography

Peer reviewers are a critical component of the publication process, ensuring quality and relevancy of articles accepted for print as well as assisting in author development. Not a reviewer but interested in joining? Visit the peer reviewer guide for the Clinical Journal of Oncology Nursing or the Oncology Nursing Forum. Access complete information on the process as well as applications to join the board. Or, contact us for additional information.

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Oncology Nursing Certification Corporation Is Pilot-Testing Employer Discount Program


Photo by Sam Capalt

Many employers recognize the benefits of having certified nursing staff on their team, but not all realize the positive impact that employer support can have on individual nurses. Reimbursing nurses who pass a certification test is a much-appreciated first step, but savvy employers realize doing more to support and recognize certified nurses can go a long way toward helping nurses overcome barriers to certification.

The Oncology Nursing Certification Corporation (ONCC) is encouraging employers of all sizes to take a broader view of certification support and is pilot-testing an Employer Discount Program in 2015. Through the program, employers will earn points for the ways in which they encourage, support or recognize certification of oncology nurses. The points will translate into discounts on certification fees. The more an employer does to encourage, support, or recognize certification of oncology nurses, the greater the discount that can be earned.

For example, providing nurses with on-site programs to prepare for certification or certification renewal, offering paid time off to take a test, linking certification to the career ladder, and educating patients on the value of certified nurses are a few of the ways employers can earn points.

Employers must meet minimum levels of support to participate in the program; the discount incentives are intended to encourage and reward them for doing more. For example, employers must agree to pay for certification at the time the candidate applies, rather than as a reimbursement. ONCC Executive Director Cyndi Miller Murphy said that “candidates have told us they’re hesitant to pay the certification fee themselves. The concept of being reimbursed upon passing can make some candidates more anxious about testing. When employers pay for certification in advance, it removes another barrier for the individual nurse.”

Employers who meet specific benchmarks for candidate volume will receive additional discounts. This two-prong approach enables employers of all sizes to participate.

ONCC will pilot test the program in 2015 with a small group of employers of different sizes, according to Murphy. If all goes well, the program will be available to more employers in 2016.

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Exclusive Articles Available Before Print

articles and coffee

Courtesy of Pixa Bay

The Oncology Nursing Forum (ONF) and the Clinical Journal of Oncology Nursing (CJON) have unveiled advanced print exclusive articles to give our readers access to important, cutting-edge content ahead of print. Articles from the journals are available on the main ONF and CJON pages. These articles are open access, meaning they are available to members and non-members alike, until they appear in print at a later date. At that time, the content will become password-protected like other articles that appear in print as online exclusives in the journals. The latest article to receive the advanced print exclusive designation is “Needs and Lifestyle Challenges of Adolescents and Young Adults With Cancer: Summary of an Institute of Medicine Livestrong Foundation Workshop” by Casey L. Daniel, Karen M. Emmons, Karen Fasciano, Brenda Nevidjon, Bernard F. Fuemmeler, and Wendy Demark-Wahnefried. Check out this timely and informative article today.

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Check Out the ONS Connect Blog


© Corbis. All rights reserved.

The official blog of ONS is written by oncology nurses for oncology nurses on a variety of topics of interest, including facing day-to-day challenges at work, juggling busy lives at home, and keeping up to date with the magnitude of information available for practicing nurses.

This month, you’ll find the following new discussions.

As a reader, join in on the conversation and connect with other oncology nurse readers by posting your own stories, tips, ideas, and suggestions in the comments section at the end of each blog post.

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Five-Minute In-Service


© Corbis. All rights reserved.

The latest Five-Minute In-Service discusses "Nursing Considerations for Ibrutinib for Hematologic Cancers."

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Ask a Team Member


© Corbis. All rights reserved.

The latest Ask a Team Member column answers the question, “What Do Oncology Nurses Need to Know About Drug Transfusions for Anemia?”

Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Membership Information

SIG Membership Benefits

  • Network with colleagues in an identified subspecialty area around the country.
  • Contribute articles for your SIG’s newsletter.
  • Participate in discussions with other SIG members.
  • Contribute to the future path of the SIG.
  • Share your expertise.
  • Support and/or mentor a colleague.
  • Receive information about the latest advancements in treatments, clinical trials, etc.
  • Participate in ONS leadership by running for SIG coordinator-elect or join SIG work groups.
  • Acquire information with a click of a mouse at https://www.ons.org/member-center/sigs including
    • Educational opportunities for your subspecialty
    • Education material on practice
    • Calls to action
    • News impacting or affecting your specific SIG
    • Newsletters
    • Communiqués
    • Meeting minutes.

Join a Virtual Community

A great way to stay connected to your SIG is to join its Virtual Community. It’s easy to do so. All you will need to do is

  • Visit the "Find a SIG" page.
  • Locate and click on the name of your SIG from the list of all ONS SIGs displayed.
  • Once on your SIG’s main page, click “Join/Renew,” and log in using your ONS Profile. Don’t have an ONS Profile? Create one today, and then return to your SIG to join.

Subscribe to Your SIG’s Virtual Community Discussion Forum
Once you have your log-in credentials, you are ready to subscribe to your SIG’s Virtual Community discussion forum. To do so,

  • Select "Log In," located next to "New User," and enter your information.
  • Next, click on the "Discussion" tab on the top right of the title bar.
  • Locate and select "Subscribe to Discussion"
  • Enter e-mail address.
  • Click "Finish."
  • You are now ready to begin participating in your SIG’s discussion forum.

Participate in Your SIG’s Virtual Community Discussion Forum

  • First, log in. (This allows others to identify you and enables you to receive notification [via e-mail] each time a response or new topic is posted.)
  • Click on "Discussion" from the top title bar.
  • Click on any posted topic to view contents and post responses.

Sign Up to Receive Your SIG’s Virtual Community Announcements
As an added feature, members also are able to register to receive their SIG’s announcements by e-mail.

  • From your SIG’s Virtual Community page, locate the "Sign Up Here to Receive Your SIG’s Announcements" section.
  • Select the "Click Here" feature, which will take you to a link to subscribe.
  • Once the "For Announcement Subscription Only" page appears select how you wish to receive your announcements.
    • As individual e-mails each time a new announcement is posted
    • One e-mail per day comprised of all new daily announcements posted
    • Opt-out, indicating that you will frequently browse your SIG’s Virtual Community page for new postings
  • Enter your e-mail address.
  • Click on "Next Page."
  • Click "Finish"
  • You are now subscribed to receive announcements.
Back to top of SIG Newsletter

Cancer Genetics

Special Interest Group Newsletter November 2015  

Cancer Genetics SIG Officers

Coordinator (2014-2016)
Catherine Belt, RN, MSN, AOCN®
Hatfield, PA

Coordinator-Elect (2015-2016)
Julia Eggert, RN, PhD, GNP-C, AGN-BC, AOCN®
Greer, SC

Patricia Kelly, DNP, APRN, CNS, AOCN®
Dallas, TX


Julia Eggert, RN, PhD, GNP-C, AOCN®
Greer, SC

Web Administrator
Lisa Aiello, RN, MSN, APN-C, AOCNS®
Philadelphia, PA

Copy Editor
Samantha Hungerford, BA
Pittsburgh, PA

Know someone who would like to receive a print copy of this newsletter?
To print a copy of this newsletter from your home or office computer, click here or on the printer icon located on the SIG Newsletter front page. Print copies of each online SIG newsletter also are available through the ONS National Office. To have a copy mailed to you or another SIG member, contact Membership/Leadership Specialist Carol DeMarco at cdemarco@ons.org or 866-257-4ONS, ext. 6230.

View past newsletters.

ONS Membership & Component Relations Department Contact Information

Brian K. Theil, CAE, Director of Membership and Component Relations Department

Diane Scheuring, MBA, CAE, CMP, Manager of Member Services

Carol DeMarco, Membership Specialist—SIGs

The Oncology Nursing Society (ONS) does not assume responsibility for the opinions expressed and information provided by authors or by Special Interest Groups (SIGs). Acceptance of advertising or corporate support does not indicate or imply endorsement of the company or its products by ONS or the SIG. Web sites listed in the SIG newsletters are provided for information only. Hosts are responsible for their own content and availability.

Oncology Nursing Society
125 Enterprise Dr.
Pittsburgh, PA 15275-1214

Back to top of SIG Newsletter